Literature DB >> 11432537

Pharmacokinetic interactions of antimalarial agents.

P T Giao1, P J de Vries.   

Abstract

Combination of antimalarial agents has been introduced as a response to widespread drug resistance. The higher number of mutations required to express complete resistance against combinations may retard the further development of resistance. Combination of drugs, especially with the artemisinin drugs, may also offer complete and rapid eradication of the parasite load in symptomatic patients and thus reduce the chance of survival of resistant strains. The advantages of combination therapy should be balanced against the increased chance of drug interactions. During the last decade, much of the pharmacokinetics and metabolic pathways of antimalarial drugs have been elucidated, including the role of the cytochrome P450 (CYP) enzyme complex. Change in protein binding is not a significant cause of interactions between antimalarial agents. CYP3A4 and CYP2C19 are frequently involved in the metabolism of antimalarial agents. Quinidine is a potent inhibitor of CYP2D6, but it appears that this enzyme does not mediate the metabolism of any other antimalarial agent. The new combinations proguanil-atovaquone and chlorproguanil-dapsone do not show significant interactions. CYP2B6 and CYP3A4 are involved in the metabolism of artemisinin and derivatives, but further studies may reveal involvement of more enzymes. Artemisinin may induce CYP2C19. Several artemisinin drugs suffer from auto-induction of the first-pass effect, resulting in a decline of bioavailability after repeated doses. The mechanism of this effect is not yet clear, but induction by other agents cannot be excluded. The combination of artemisinin drugs with mefloquine and the fixed combination artemether-lumefantrine have been studied widely, and no significant drug interactions have been found. The artemisinin drugs will be used at an increasing rate, particularly in combination with other agents. Although clinical studies have so far not shown any significant interactions, drug interactions should be given appropriate attention when other combinations are used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432537     DOI: 10.2165/00003088-200140050-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  172 in total

1.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

2.  Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19.

Authors:  K Mihara; U S Svensson; G Tybring; T N Hai; L Bertilsson; M Ashton
Journal:  Fundam Clin Pharmacol       Date:  1999       Impact factor: 2.748

3.  Cardiac effect of halofantrine.

Authors:  J Karbwang; K Na Bangchang; D Bunnag; T Harinasuta; P Laothavorn
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

4.  Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults.

Authors:  M Ashton; T N Hai; N D Sy; D X Huong; N Van Huong; N T Niêu; L D Công
Journal:  Drug Metab Dispos       Date:  1998-01       Impact factor: 3.922

5.  Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.

Authors:  A M Nzila; E K Mberu; J Sulo; H Dayo; P A Winstanley; C H Sibley; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment.

Authors:  S Wanwimolruk; S M Wong; H Zhang; P F Coville; R J Walker
Journal:  J Pharm Pharmacol       Date:  1995-11       Impact factor: 3.765

Review 7.  Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria.

Authors:  P J de Vries; T K Dien
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

8.  The multiple dose pharmacokinetics of proguanil.

Authors:  N A Helsby; G Edwards; A M Breckenridge; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

9.  Atovaquone and proguanil for Plasmodium falciparum malaria.

Authors:  P D Radloff; J Philipps; M Nkeyi; D Hutchinson; P G Kremsner
Journal:  Lancet       Date:  1996-06-01       Impact factor: 79.321

10.  A mechanism for the synergistic antimalarial action of atovaquone and proguanil.

Authors:  I K Srivastava; A B Vaidya
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

View more
  31 in total

1.  Assessment of the effect of mefloquine on artesunate pharmacokinetics in healthy male volunteers.

Authors:  Timothy M E Davis; Michelle England; Anne-Marie Dunlop; Madhu Page-Sharp; Nathalie Cambon; Thomas G Keller; János L Heidecker; Kenneth F Ilett
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

Review 2.  Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals.

Authors:  Tony K L Kiang; Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

3.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

4.  Treatment with coartem (artemether-lumefantrine) in Papua New Guinea.

Authors:  Sonja Schoepflin; Enmoore Lin; Benson Kiniboro; Jeana T DaRe; Rajeev K Mehlotra; Peter A Zimmerman; Ivo Mueller; Ingrid Felger
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

5.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

6.  Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  J Pharm Pharmacol       Date:  2009-04       Impact factor: 3.765

Review 7.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

8.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.

Authors:  Doaa A Elsherbiny; Sara A Asimus; Mats O Karlsson; Michael Ashton; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-03-19       Impact factor: 2.745

10.  A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.

Authors:  Eva Maria Hodel; Serej D Ley; Weihong Qi; Frédéric Ariey; Blaise Genton; Hans-Peter Beck
Journal:  Malar J       Date:  2009-12-09       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.